The Life Sciences team advised Mariana Oncology on its acquisition by Novartis for $1 billion upfront and up to $750 million in potential milestone payments. The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis. The transaction is subject to customary closing conditions.

Mariana Oncology is a fully integrated, radiopharmaceutical company pioneering a new standard of care in cancer treatment – targeted peptide-based radioligand therapeutics (RLTs) designed to maximize tumor penetration while minimizing toxicity. Mariana is comprised of some of the world’s leading experts in radiopharmaceutical science and manufacturing who together are pioneering innovations in end-to-end discovery, development and delivery of radioligand therapeutics.

The Goodwin team was led by Laura U. Gulick, Sam Beavers and Kingsley Taft and included Joseph Jung Hyuk Yim, Nuha Kabir and Amine Assouad; Alan Wang and Christopher Zhong (IPTS); Arman Oruc, Andrew Jensen, Elliot Silver, Simone Waterbury, Kevin Walsh and Anuj Ghai (Antitrust); Sarah Bock, Andre Amorim and Justine Park (Compensation and Benefits); Dan Karelitz, Tyler Mayo and Erika Pey (Tax); Richard Matheny, Gozde Guckaya, Julie Tibbets and Matt Wetzel (Regulatory); and Jennifer Fay and Lauren NuDelman (Labor and Employment), with invaluable assistance from Scott Zilora, Matthew Mancini and Ai Tajima.

For additional details on the acquisition, please read the press release and coverage in Reuters, Fierce Biotech and STAT.